ISRCTN61976169 https://doi.org/10.1186/ISRCTN61976169

Therapy of frequent relapsing, steroid-sensitive nephrotic syndrome in childhood: efficacy of mycophenolate mofetil versus cyclosporin A

Submission date 24/03/2006	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 26/05/2006	**Overall study status** Completed	
Last Edited 20/09/2007	**Condition category** Urological and Genital Diseases	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mrs Jutta Gellermann

Contact details
Augustenburger Platz 1
Berlin
Germany
13353

Additional identifiers

Protocol serial number
ML 16622

Study information

Scientific Title

Study objectives

Immunosuppressive therapy with mycophenolate mofetil (MMF) is as effective as cyclosporin A in preventing relapses of the nephrotic syndrome.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics approval received from the Ethics Committee of Charité - University Medicine Berlin (Germany) on the 2nd December 2002 (ref: 1656/Si 238).

Study design
Multicentre, randomised, open-labelled, cross-over trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Idiopathic nephrotic syndrome

Interventions
Immunosuppressive therapy with MMF versus cyclosporin A.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Mycophenolate mofetil, cyclosporin A

Primary outcome(s)
Number of relapses during the observation period

Key secondary outcome(s))
Decrease in GFR, hypertension and hyperlipidemia during the observation period

Completion date
31/12/2008

Eligibility

Key inclusion criteria

1. Children aged 3 - 17 years
2. Frequent relapses of steroid-sensitive nephrotic syndrome, associated with minimal changes on renal biopsy
3. Glomerular Filtration Rate (GFR) greater than 70 ml/min

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Child

Lower age limit
3 years

Upper age limit
17 years

Sex
All

Key exclusion criteria
1. Other histological findings on renal biopsy
2. Other severe concomittant diseases
3. Decreased GFR

Date of first enrolment
01/01/2004

Date of final enrolment
31/12/2008

Locations

Countries of recruitment
Germany

Study participating centre
Augustenburger Platz 1
Berlin
Germany
13353

Sponsor information

Organisation
Hoffmann-La Roche AG (Germany)

ROR
https://ror.org/00sh68184

Funder(s)

Funder type
Industry

Funder Name
Hoffmann La Roche AG (Germany)

Funder Name
Charité - University Medicine Berlin (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/01/2004		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes